Treatment Details – 6.6 months
|Patients: This Phase II study involved 20 patients with malignant mesothelioma who could not be treated by surgery or radiation alone.|
Treatment: The treatment consisted of administration of the drug edatrexate with leucovorin.
Toxicity: Grade 3-4 toxicities included hematologic, infection, muscositis, esophagitis/dysphagia, dermatologic, anorexia, malaise/fatigue, cardiac, pulmonary, hepatic, and neurologic.
Results: The median survival duration was 6.6 months.